DH
Therapeutic Areas
Clinuvel Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SCENESSE® (afamelanotide) | Erythropoietic Protoporphyria (EPP) | Approved |
Leadership Team at Clinuvel Pharmaceuticals
DP
Dr. Philippe Wolgen
Chief Executive Officer
DR
Derek R. H. Lamb
Chief Financial Officer
DD
Dr. Dennis Wright
Chief Scientific Officer
DL
Dr. Laura K. Ferraresso
Global Head of Legal and Corporate Affairs
BJ
Bradford J. Dufton
Company Secretary and Global Head of Corporate Services
SM
Stan McLiesh
Chair